| [1] |
Cruz-Ramos M, Garcia-Foncillas J . CAR-T cell and personalized medicine[J]. Adv Exp Med Biol, 2019(1168):131-145.
|
| [2] |
Gorabi AM, Hajighasemi S, Sathyapalan T , et al. Cell transfer-based immunotherapies in cancer: A review[J]. IUBMB Life, 72(4):790-800.
|
| [3] |
钱其军, 吴孟超 . 肿瘤过继细胞治疗----老故事新演绎[J]. 中国肿瘤生物治疗杂志, 2011,18(1):1-6.
|
| [4] |
Wculek SK, Cueto FJ, Mujal AM , et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2020,20(1):7-24.
|
| [5] |
Jiang N, Qiao G, Wang X , et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancrea-tic cancer: A prospective study[J]. Clin Cancer Res, 2017,23(17):5066-5073.
|
| [6] |
Wang X, Ren J, Zhang J , et al. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)[J]. Clin Transl Oncol, 2016,18(1):82-87.
|
| [7] |
Wang S, Wang X, Zhou X , et al.DC-CIK as a widely applicable cancer immunotherapy[J/OL].Expert Opin Biol Ther, ( 2020 -02-13). doi: 10.1080/14712598.2020.1728250.
|
| [8] |
Routy B, Gopalakrishnan V, Daillère R , et al. The gut microbiota influences anticancer immunosurveillance and general health[J]. Nat Rev Clin Oncol, 2018,15(6):382-396.
|
| [9] |
Goubet AG, Daillère R, Routy B , et al. The impact of the intestinal microbiota in therapeutic responses against cancer[J]. C R Biol, 2018,341(5):284-289.
|
| [10] |
Havel JJ, Chowell D, Chan TA . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Cancer, 2019,19(3):133-150.
|
| [11] |
Sanmamed MF, Chen L . A paradigm shift in cancer immunotherapy: From enhancement to normalization[J]. Cell, 2018,175(2):313-326.
|
| [12] |
Li XV, Leonardi I, Iliev ID . Gut mycobiota in immunity and inflammatory disease[J]. Immunity, 2019,50(6):1365-1379.
|
| [13] |
Kamada N, Seo SU, Chen GY , et al. Role of the gut microbiota in immunity and inflammatory disease[J]. Nat Rev Immunol, 2013,13(5):321-335.
|
| [14] |
Round JL, Lee SM, Li J , et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota[J]. Science, 2011,332(6032):974-977.
|
| [15] |
Kim M, Galan C, Hill AA , et al. Critical role for the microbiota in CX3CR1 + intestinal mononuclear phagocyte regulation of intestinal T cell responses [J]. Immunity, 2018,49(1):151-163.
|
| [16] |
Fitzgibbon G, Mills KHG . The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention[J]. Eur J Immunol, 2020,50(3):326-337.
|
| [17] |
Karin M, Jobin C, Balkwill F . Chemotherapy, immunity and microbiota: a new triumvirate?[J]. Nat Med, 2014,20(2):126-127.
|
| [18] |
Ganal SC, Sanos SL, Kallfass C , et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota[J]. Immunity, 2012,37(1):171-186.
|
| [19] |
Abid MB, Shah NN, Maatman TC , et al. Gut microbiome and CAR-T therapy[J]. Exp Hematol Oncol, 2019(8):31.
|
| [20] |
Paulos CM, Wrzesinski C, Kaiser A , et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via TLR4 signaling [J]. J Clin Invest, 2007,117(8):2197-2204.
|
| [21] |
Dudley ME, Yang JC, Sherry R , et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens[J]. J Clin Oncol, 2008,26(32):5233-5239.
|
| [22] |
Uribe-Herranz M, Bittinger K, Rafail S , et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12[J]. JCI Insight, 2018,3(4):e94952.
|
| [23] |
Tanoue T, Morita S, Plichta DR , et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity[J]. Nature, 2019,565(7741):600-605.
|
| [24] |
Duell J, Dittrich M, Bedke T , et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL[J]. Leukemia, 2017,31(10):2181-2190.
|
| [25] |
Otoshi T, Nagano T, Tachihara M , et al. Possible biomarkers for cancer immunotherapy[J]. Cancers (Basel), 2019,11(7):935.
|